In Brief: InSite Vision/Bausch & Lomb
Executive Summary
InSite Vision/Bausch & Lomb: Announce global agreement covering the manufacturing of potential InSite Vision products, the worldwide marketing of PilaSite (pilocarpine) for glaucoma and joint development of the DuraSite eyedrop-based sustained drug delivery system. B&L will make a $2 mil. equity investment, provide up to $2 mil. in R&D funding and pay royalties on future products. PilaSite and BetaSite (levobunolol) for glaucoma both have completed Phase III trials, Alameda, Calif.-based InSite notes; the B&L deal will allow the products to proceed to NDA filings "without incurring substantial infrastructure costs required to develop our own large-scale production facilities," InSite notes...